New treatment option for older patients with blood cancer
Researchers are a step closer to offering older patients with an aggressive blood cancer, acute myeloid leukaemia (AML), a new less-toxic treatment option.
Visitor information – Everything you need to know about visiting our sites.
Our group focuses on several haematopoietic transcription factors recurrently mutated in acute lymphoblastic and myeloid leukemias (ALL and AML) and their role in tumour suppressor gene function.
The laboratory also uses leukaemias derived from mouse models to screen for genes critical to leukaemia maintenance, which represent potential novel drug targets.
Researchers are a step closer to offering older patients with an aggressive blood cancer, acute myeloid leukaemia (AML), a new less-toxic treatment option.
The Alfred and Monash University are set to establish Australia’s first dedicated blood cancer research centre, thanks to a $1.2 million grant from the Australian Cancer Research Foundation (ACRF).